Brain Cells, Inc.

Website Links

Description

Chief Executive Officer Mr. Schoeneck joined BCI in September 2005 from ActivX BioSciences, a proteomics-based drug development company, where he served as CEO and led the strategic sale of the company to Kyorin Pharmaceuticals of Japan in December 2004. Prior to ActivX, Mr. Schoeneck was at Prometheus Laboratories Inc. where he served as President and CEO for over three years, having previously served as President and COO. While at Prometheus, he led their business strategy and operations during a period of exceptional growth and transformation. Under his leadership, Prometheus was recognized as #3 on the Inc. 500 list of the fastest growing private companies in America and as the San Diego Venture Group success story of the year (2002). Prior to joining Prometheus, Mr. Schoeneck was Vice President and General Manager, Immunology Business Unit of Centocor, Inc., a division of Johnson & Johnson. His responsibilities included leading the development and launch of Remicade® on a worldwide basis, including the formation of a strategic partnership with Schering-Plough Corporation. Before that assignment, Mr. Schoeneck served as Centocor's Vice President of Marketing and Commercial Development. Prior to Centocor, he spent 13 years at Rhone-Poulenc Rorer, Inc. (now Aventis) serving in various positions of increasing responsibility. Top

Products & services